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ABSTRACT
Objectives: In Thailand, policymakers have come under
increasing pressure to use economic evaluation to inform
health-care resource allocation decisions, especially after the
introduction of the Universal Health Insurance Coverage
(UC) scheme. This article presents qualitative ﬁndings from
research that assessed a range of policymakers’ perspectives
on the acceptability of using economic evaluation for the
development of health-care beneﬁt packages in Thailand. The
policy analysis examined their opinions about existing
decision-making processes for including health interventions
in the UC beneﬁt package, their understanding of health
economic evaluation, and their attitudes, acceptance, and
values relating to the use of the method.
Methods: Semistructured interviews were conducted with 36
policy actors who play a major role or have some input into
health resource allocation decisions within the Thai health-
care system. These included 14 senior policymakers at the
national level, 5 hospital directors, 10 health professionals,
and 7 academics.
Results and Conclusions: Policy actors thought that eco-
nomic evaluation information was relevant for decision-
making because of the increasing need for rationing and more
transparent criteria for making UC coverage decisions. Nev-
ertheless, they raised several difﬁculties with using economic
evaluation that would pose barriers to its introduction,
including distrust in the method, conﬂicting philosophical
positions and priorities compared to that of “health maximi-
zation,” organizational allegiances, existing decision-making
procedures that would be hard to change, and concerns
about political pressure and acceptability.
Keywords: decision-making, economic evaluation, health-
care beneﬁt package, Thailand.
Introduction
Health economic evaluation is designed to guide
explicit health resource allocation decisions by com-
paring the marginal costs and consequences of alter-
native health-care interventions. In some industrial
countries, economic evaluation studies are increasingly
being used to inform more explicit and transparent
health-care coverage decisions [1]. Nevertheless, in
low- and middle-income countries, economic evalua-
tion has rarely been used as a tool to inform decisions
about the content of health-care beneﬁt packages [2,3].
In Thailand in recent years, as in other Asian coun-
tries, policymakers have come under increasing pres-
sure to justify resource allocation decisions in the
health sector [4,5]. The Universal Health Insurance
Coverage (UC) policy implemented in 2001 offers a
package of health-care interventions at public facilities
to all Thai citizens not covered by other beneﬁt pack-
ages [6]. Nevertheless, as a result of rapid implemen-
tation, only limited evidence was used to guide
decisions on the services included in the UC package.
The government now needs to clarify and make more
transparent the beneﬁt package, especially for high-
cost interventions, which are likely to absorb a dispro-
portionate amount of resources and are an attractive
target for providers to cut provision to contain costs.
Two broad types of barrier to the introduction of
economic evaluation into policy decision-making
can be envisaged for middle-income countries like
Thailand. First, there is a very limited supply of good
quality economic evaluation studies [7,8]; In Thailand,
policymakers face these informational barriers [9].
Second, even if economic evaluation data were avail-
able, decision-makers may not understand, accept, or
be willing to use economic evaluation as a tool in their
decision-making on resource allocation. As analysts
have argued for many years, policy decisions are not
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just technical questions but are inherently political
processes, involving questions of power and resources
[10]; for example, decision-makers will be aware that
the exclusion or inclusion of an expensive treatment in
the UC package will have important implications for
sections of the public, government expenditure, their
colleagues who have to implement the decision, and
perhaps the government’s political standing.
In industrial countries, there have been a small
number of studies on policy actors’ attitudes to eco-
nomic evaluation as a tool in decision-making for
health-care priority setting [11,12]. In middle-income
countries, where the pressure for more explicit ration-
ing is growing, there have been even fewer studies to
explore decision-makers’ attitudes toward and accep-
tance of economic evaluation [3].
This article presents ﬁndings from a larger piece of
research that assessed the feasibility of doing economic
evaluation studies in Thailand (by undertaking eco-
nomic evaluation studies for two high-cost inter-
ventions) and the acceptability of using economic
evaluation as a tool for the development of health-care
beneﬁt package. It focuses on Thai policy actors’
general understanding, acceptance and valuation of
economic evaluation, the multiple factors that they
must weigh up in their decision-making about health-
care coverage, and therefore the difﬁculties of intro-
ducing economic evaluation into this decision-making.
Design and Methods
Semistructured face-to-face interviews were used to
generate qualitative data on policy actors’ attitudes
toward economic evaluation. A semistructured inter-
view technique could capture the complexity and
depth of policy actors’ perspectives, and allowed the
researcher to explore a wide variety of issues, enabled
ﬂexibility in the discussion, and gave the respondents
room to tell their own story [13].
Respondents
A broad deﬁnition of a policy actor was adopted for
this study, deﬁned as any individual or group involved
in the public policy process, for example, working
to change or maintain the policy agenda, presenting
information that feeds into policy processes, sitting on
committees that make policy decisions, and those
actors involved in policy implementation [10].
Respondents were selected purposively to cover four
groups of policy actors who play a role in health
resource allocation within the Thai health-care system.
These were: 1) policymakers at the national level who
were senior administrators at the Ministry of Public
Health (MOPH) and National Health Security Ofﬁce
(NHSO; NHSO is an autonomous health-care institu-
tion in Thailand that manages the UC scheme); 2)
hospital directors who are responsible for allocating
resources within Thai health-care institutions; 3)
health professionals who are responsible for resource
allocation decisions at the patient-level; and 4) aca-
demics who produce and/or use economic evaluation
information to inform decision-makers.
The qualitative data generated from a purposive
sample of policy actors is not intended to be “repre-
sentative” in statistical terms. Rather, the data can be
used to build conceptual understanding and explana-
tions of actors’ attitudes, positions, and vested inter-
ests relating to economic evaluation. The policy
relevance of the qualitative material did rely on ensur-
ing that an appropriate range of policy actors for
this particular setting were covered, to ensure that a
“typical” range of perspectives were captured [14].
An invitation letter and consent form were sent to
each of 38 potential participants. For policymakers at
the national level, letters were sent to the top seven
senior administrators at the MOPH, both politicians
and bureaucrats, and the top seven senior administra-
tors of the NHSO. The ﬁve hospital directors invited to
an interview were based at the public hospitals where
the authors had previously conducted the two eco-
nomic evaluation studies [15,16]. The invitation letters
were also sent to health professionals at those ﬁve
public hospitals, selected purposively to include dif-
ferent medical specialists, including two internists,
two surgeons, two nephrologists, one pediatrician, one
oncologist, one ophthalmologist, and one otorhino-
laryngologist. Seven Thai academics whose names
were identiﬁed from publications about health-care
rationing were also invited to participate in the study.
Thirty-six respondents were interviewed between
December 2004 and May 2005 (95% response rate).
Table 1 presents the characteristics of all respondents:
They were predominantly male, more than 45 years
old, and medically qualiﬁed (34 out of 36 respondents
had qualiﬁed in medicine), which reﬂects the compo-
sition of senior management in the health sector in
Thailand more generally. Only six respondents had
had training in health economics.
Interview Schedule
It was expected that many respondents would have
limited knowledge about health economic evaluation,
so ﬁrst the interviewer asked if respondents knew
about cost-minimization, cost-effectiveness, cost-
utility, and cost–beneﬁt analysis. Those who revealed
that they knew about these terms were asked to give
a brief explanation to verify their understanding.
Regardless of whether respondents stated they under-
stood about economic evaluation, every respondent
was given a brief introduction to the subject to enable
them to understand the basic concept and its applica-
tions. Respondents were free to ask questions after the
explanations and before the interview moved on to
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further discussion. The interview schedule then con-
sisted of questions on the respondents’:
1. opinions about existing criteria and decision-
making processes for including health interven-
tions in the UC beneﬁt package;
2. understanding about health economic evaluation
and their experiences of using it;
3. attitudes, acceptance, and values relating to the
use of economic evaluation for development of the
beneﬁt package;
4. opinions about the reliability and acceptability of
economic evaluation evidence.
Analysis
All interviews were tape-recorded and transcribed ver-
batim. The ﬁrst author read all the Thai transcripts to
become familiar with the data and then each transcript
was read again and a list of codes developed, with
sections of the text allocated speciﬁc codes. The codes
(or themes) that emerged were based on the words,
concepts, and categories used by the respondents
themselves but were inevitably also related to the con-
cepts being explored through the question guideline.
After coding, it was possible to explore the similarities
and differences between respondents’ perspectives on
economic evaluation. One of our interests was to
explore whether the respondents’ different positions
and duties inﬂuenced their understanding and accep-
tance of economic evaluation as a tool for health-care
rationing.
Results
Opinions about Existing Criteria and Decision-Making
Processes for Including Health Interventions in the UC
Beneﬁt Package
Policymakers at the national level, located in the
NHSO and MOPH, and who had been involved in the
development of the UC beneﬁt package, reported that
a range of factors inﬂuenced the inclusion or exclusion
of interventions: the number of patients that needed
to be treated, severity of disease, cost of interventions
and affordability, equity of access, and coverage of
similar services by other health insurance schemes. The
reasons for using these criteria had been a familiarity
with them, and because the evidence was available
in administrative or routine databases. These policy
actors admitted that budgetary impacts had been of
particular interest because it was their responsibility to
identify the budget funding for any new intervention
to be included in the package. They also claimed that
political pressure had played a signiﬁcant role in the
decision-making process. They used the example of the
inclusion of antiretroviral treatment (ART) for HIV/
AIDS in the package, which they believed was based
primarily on political pressure and inﬂuence:
At that time the government had just appointed an
expert committee to consider it (the inclusion of
ART), but the committee had not reached their
conclusion when the government announced pub-
licly the inclusion of ART on “World AIDS Day” in
2002.
There had been no formal criteria for making
health-care coverage decisions and none of the policy-
makers had used economic evaluation, or were cur-
rently using it, when they had to make a decision or
provide policy advice.
Hospital directors had not been involved in the
development of the UC beneﬁt package and had little
idea about the criteria used to inform coverage deci-
sions. At hospital level, none had used economic evalu-
ation to make resource allocation decisions. Similarly,
health professionals working in the ﬁve hospitals did
not know the criteria used for including or excluding
interventions from the package but stressed the need
for more transparent decision-making processes for
making coverage decisions. They argued that because
they are at the frontline of service delivery and select
the medicines listed on the hospital formulary, they
should be involved in decision-making processes relat-
ing to the UC beneﬁt package:
We know our patients more than politicians and
policymakers do, so why not allow us to consider
the coverage of interventions that we have to
provide?
Some but not all of the academics had been involved
in the development of the UC beneﬁt package, and
those involved argued that even if the decisions were







No. of respondents 14 5 10 7 36
No. of female respondents 0 0 2 0 2
Average age (years) 53 49 48 51 50
No. of respondents who
qualiﬁed in medicine
14 (100%) 5 (100%) 10 (100%) 5 (71%) 34 (94%)
No. of respondents who had
trained in health economics
2 (14%) 0 0 4 (57%) 6 (17%)
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made based on the best available information and in
the best interest of society, there was room for
improvement. The rationing criteria had been implicit
and required greater transparency, including a system-
atic framework to help decision-makers defend their
decisions. Academics also argued that the public
needed to be involved in the process, although they
acknowledged the difﬁculty of involving the public in
health-care rationing.
Knowledge and Understanding
Among the 14 policymakers at the national level, only
4 (29%) were able to deﬁne the concept of economic
evaluation correctly. All ﬁve hospital directors had
heard about economic evaluation, but none were able
to deﬁne correctly the concept and its applications, for
example, describing it as a method that compares only
the costs of interventions but not the health outcomes.
In Thailand, health economics is not part of the
medical curriculum and therefore the 10 health profes-
sionals had very limited knowledge about economic
evaluation. They misunderstood economic evaluation
and referred to it as a method for unit-cost analysis or
a cost-controlling instrument.
Not surprisingly, the seven academics had better
knowledge and understanding of economic evaluation
compared to the other groups. Five had completed or
were undertaking formal training in health economics
and three of them had published at least one article
about health economic evaluation in national or inter-
national peer-reviewed journals.
Attitudes, Acceptance, and Values Relating to the Use of
Economic Evaluation
After giving an explanation of economic evaluation
and verifying their understanding, all of the respon-
dents were asked to discuss its potential relevance for
decision-making. Policymakers at the national level
considered economic evaluation to be a relevant tool
for helping them make decisions about the acceptance
or rejection of a technology, and that it had the poten-
tial to improve the existing implicit and sometimes
political criteria. Nevertheless, they argued strongly
that economic evaluation information should not be
the only criterion for deciding the content of the
package. Four policymakers (of 14, 29%) supported
its use as a major criterion and 9 (64%) claimed that it
would have to be one of many factors considered.
They argued, for example, that political pressures had
played a role in making past coverage decisions (see
the example of ART previously mentioned) and that
these political considerations made by the Minister of
Health were legitimate, even if they included some
cost-ineffective interventions. They were concerned
that if economic evaluation was the only criterion
used, the power to make coverage decisions would be
transferred from legitimate political representatives to
academics.
Policymakers were also concerned about the com-
plexity of the method, which would make it difﬁcult to
communicate to the public and in turn might affect
public perceptions and levels of support for their
decisions:
There will not be much popular support for the use
of cost-utility analysis because people cannot under-
stand what a QALY really means. It is very subjec-
tive and difﬁcult to give a clear explanation. Only
researchers can understand and accept this but lay-
persons or even doctors, I believe, do not under-
stand. (national policymaker)
National policymakers were conﬁdent about their
decision-making skills and their ability to incorporate
and balance numerous considerations. In particular
they argued that they had to balance several public
health insurance objectives: It should not only maxi-
mize the aggregate health beneﬁts of the population
(i.e., a utilitarian perspective that underpins economic
evaluation), but also offer services that can improve
equity in health across subpopulations, develop “social
solidarity” by giving higher priority to services for
vulnerable populations, and protect against the ﬁnan-
cial risks of catastrophic health expenditures.
One senior administrator questioned further the
appropriateness of the utilitarian concept for resource
allocation in health care (maximizing health beneﬁt)
by referring to the Buddhist philosophy of the “Middle
Way,” implying that people may not want their health-
care system to make people live as long as possible (to
maximize quality-adjusted life-years [QALYs]) because
this may cause cravings to live longer but not increase
happiness.
Hospital directors also argued that economic evalu-
ation had the potential to aid health technology cov-
erage decisions. In fact a larger proportion of the
hospital directors compared to the national policy-
makers supported the idea of economic evaluation
being the sole or major criterion for resource alloca-
tion decisions: two out of ﬁve stated that economic
evaluation information should be the only criterion;
two supported its use as a major criterion; and only
one supported its use alongside several other criteria
such as feasibility (whether there were the necessary
infrastructure and human resources to provide a par-
ticular service). Nevertheless, the overall affordability
for the hospital of introducing an intervention was a
key concern among hospital directors who are respon-
sible for balancing the hospital budget. They believed
that there would be increasing cost pressure on health-
care providers due to new technologies and an aging
population, and at the time of the interview expressed
their frustration with the under-reimbursement they
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were receiving from the central MOPH under the
existing high-cost beneﬁt package.
The health professionals, being closer to patients on
a daily basis and prescribing numerous treatments,
admitted the necessity of rationing in health care and
understood the difﬁculties of the rationing process.
None of them opposed the use of economic evaluation
for making health-care coverage decisions, but their
overall position on this matter was similar to the poli-
cymakers. None thought that it should be the only
criterion for the development of the beneﬁt package,
with half (5 out of 10) arguing that it should be a
major criterion and the other half arguing that it is one
of several criteria, such as severity of disease, social
solidarity, and equity.
Health professionals also raised a similar concern to
that raised by national policymakers. They feared that
it would be difﬁcult to develop a simple message to
communicate to the public about economic evaluation.
Related to this concern, they anticipated that the pub-
lic’s trust and respect for them would be undermined
if they could not work in the best interests of their
patients and had to apply rationing decisions based on
cost-effectiveness criteria.
All the academics argued that the use of economic
evaluation was a way to make policy decisions more
transparent. They commented on the current lack of
explicit criteria used for the selection of health inter-
ventions for the beneﬁt package:
Some people think that utility is subjective but we
are currently using no evidence which means it is
even more subjective. (academic)
Three out of seven academics endorsed the use of
economic evaluation as the sole criterion for develop-
ment of the beneﬁt package, and another three sup-
ported the use of economic evaluation information as
a major criterion. Only one academic was reluctant
to use economic evaluation information over other
factors, for example equity, to make coverage
decisions.
The majority of academics supported the speciﬁc
use of cost-utility analysis because it was necessary to
make resource allocation decisions across health tech-
nologies, and although not a perfect tool, it is the only
method now accepted internationally.
Opinions about the Reliability and Acceptability
of Evidence
Several respondents referred to methodological issues
that would affect policy actors’ trust in and acceptance
of economic evaluation data. There was a consensus
across the policy actor categories that evidence must be
derived from the Thai setting and not transferred from
other countries. The policy actors’ concern about the
transfer of economic evaluation results, particularly
from North America or Europe to a country like Thai-
land, reﬂected those raised in the health economics
literature [17,18]. For example, policymakers at the
national level and hospital directors were concerned
about the differences in both costs and health state
preferences used in evaluations in other settings. Hos-
pital directors also noted that a barrier to using eco-
nomic evaluation was the lack of studies conducted in
Thailand. They thought that substantial evidence was
needed to inform coverage decisions, but that there
was limited expertise to produce, analyze, and inter-
pret the evidence. Health professionals worried about
the application of clinical outcomes from trials con-
ducted in the United States or European countries and
also expressed serious doubts about the soundness of
the method. They were not clear whether it was pos-
sible to simplify complex health and nonhealth out-
comes into a single utility unit such as a QALY or
disability adjusted life year (DALY).
Policy actors also noted the importance of a rigor-
ous and unbiased process for selecting health technolo-
gies for assessment. One of the more experienced
national level policymakers at the NHSO expressed an
interest to learn about selection processes for technol-
ogy assessment that would be unbiased and so most
effective policy decision-making.
Two of the ﬁve academics also stated that they
would not support the use of economic evaluation if
the process for selecting technology to be appraised
was not well organized. If decisions were left to indi-
vidual investigators, or motivated by government or
commercial sponsors, the assessments might not cover
society’s best interests.
All respondents favored evidence produced by aca-
demics or independent organizations over evidence
from the pharmaceutical industry. Several suggested
that responsible bodies for conducting economic
evaluation in Thailand should be “transparent,”
“accountable,” “impartial,” “widely acceptable,” and
“skillful.” Although academics considered that the
NHSO and other health-care purchasers should not be
directly involved in the evaluation process due to pos-
sible conﬂicts of interest, they suggested that these
public bodies should be the main funding sources for
economic evaluation studies in Thailand.
Discussion
Although health economic evaluation has been widely
disseminated in the academic literature and found
favor in real policy decisions in some developed coun-
tries, the tool has never occupied a place in the health
policy arena of developing countries even though
resources are scarcer and there is a need for ration-
ing. This study is the ﬁrst to explore among policy
actors the potential opportunities and difﬁculties or
complexities of introducing the method to develop a
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public health-care beneﬁt package in a middle-income
country, Thailand.
Opportunities for Introducing Economic Evaluation
The interviews revealed some shifts in policy context
that had increased policy actors’ support for economic
evaluation. First, increasing pressure on constrained
resources was the most important factor driving stake-
holders at every level to care about priority setting.
Policymakers at the national level, hospital directors,
and even health professionals working with patients
realized that it is impossible to include every health
service that could beneﬁt patients within the UC
beneﬁt package and that the need to ration limited
resources would be even greater in the future. Increas-
ing pressure for more efﬁcient use of public resources
stemmed from rapid increases in the availability and
cost of new health technologies and an epidemiological
transition that had increased demand for expensive
interventions.
Second, and related to the above resource pressures,
policy actors voiced the need for more transparent
decision-making. It was evident that current decision-
making practices lacked transparency and participa-
tion by stakeholders such as hospital directors, health
professionals, or even the public. Policy actors also
accepted that economic evaluation could be a means of
strengthening the legitimacy of their decisions because
it was a rational basis for explaining their decisions
and gaining acceptance from health-care stakeholders
and the public.
Potential Difﬁculties of Introducing Economic Evaluation
Although policy actors thought that economic evalua-
tion information was potentially useful, it was rarely
accepted as the only criterion for making coverage
decisions; respondents voiced several difﬁculties or
complexities. Figure 1 presents a simple framework
for categorizing these reservations or difﬁculties with
using economic evaluation expressed by policy actors.
It illustrates how their attitudes toward economic
evaluation must be understood within wider contexts,
in particular their organizational allegiances and the
institutionalized “ways of doing things” within these
organizations or among their social and professional
groups, which are reinforced by the norms, rules, and
values of those groups or wider society.
Following the numbered components in Figure 1,
the ﬁrst barrier to the adoption of economic evaluation
to inform the UC beneﬁt package relates to the avail-
ability of Thai studies of adequate quality. The respon-
dents rejected the use of foreign data because they were
aware of diversities in costs and outcomes that might
occur from the same intervention in different settings
(see [9] for a review of these informational barriers in
more detail).
The second barrier against the use of economic
evaluation relates to policy actors’ limited understand-
ing of it, revealed by their misuse of terminology and
frequent failure to distinguish between it and cost
analysis. Lack of training in health economics for
medical students in Thailand makes this ﬁnding across
respondents unsurprising. Without improved under-
standing among national policymakers, hospital direc-
tors, and health professionals, the use of economic
evaluation in decision-making in Thailand is unlikely
to happen. Some respondents also revealed a lack of
trust in economic evaluation methods and results that
stemmed partly from the fact that economic evalua-
tions are complex simulations and biases can be intro-
duced in many ways at various steps in the analysis.
Many of these problems were well described by aca-
demic respondents and are fully supported by evidence
[9]. Policymakers also believed that the results could
be manipulated unless studies were conducted trans-
parently and by neutral agencies.
Figure 1 The difﬁculties and complexities
of introducing economic evaluation into
health technology coverage decision-making
processes.
4a. Organizational allegiances
4b. Institutionalized ways of doing things
5. Political context & pressure




Social & economic context 
2. Understanding of & trust in 
economic evaluation methods
3. Philosophical & ethical 
positions
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A third difﬁculty with the introduction of economic
evaluation was based on philosophical and ethical
positions that contrasted with the philosophy of
“health maximization” underpinning economic eva-
luation. Some respondents expressed doubt as to
whether the utilitarian notion of “QALY maximiza-
tion” would lead to an equitable or just distribution of
scarce health resources, or would be in the best inter-
ests of society. They said it was also morally justiﬁable
to offer interventions that are less cost-effective to
more vulnerable groups in society such as the young or
those of old age, those living in poverty, or living with
disabilities. In their opinion, the public’s acceptance of
economic evaluation would be limited if the societal
values of equity or justice were not incorporated into
decision-making.
Fourth, organizational allegiances and institution-
alized modes of thinking and behavior made policy
actors cautious about the introduction of economic
evaluation, although to differing degrees. For example,
policymakers at the national level were allied to the
objectives of these organizations, which are not solely
to improve (or maximize) the overall health of the
population but also to promote equity in health care
and overall social welfare.
Hospital directors operate in a slightly different
organizational environment where the primary objec-
tive is to maintain the overall ﬁnancial sustainability of
the hospital, delivering health services within budget
and containing costs wherever possible. Moreover, the
UC capitation payment system provides incentives for
hospital directors to contain costs because the hospital
is relatively autonomous ﬁnancially and responsible
for overspending in any given year (and can retain any
underspending). Hospital directors’ relatively more
enthusiastic acceptance of economic evaluation as a
tool to promote efﬁciency was therefore not surprising.
Equity in health care was a relevant but relatively less
pressing organizational concern.
Social institutions refer to “ways of doing things,”
which might be formalized through law or be less
formalized rules governing behaviors based on norms
and values. A dominant mode of thinking and behav-
ior instilled in medical professionals is the primacy of
the right to treatment and health. In Thailand, the
right to treatment (traditional and later allopathic)
without concern for economic issues has a long history
[19], and although the Thai health-care system has
evolved, the health profession has retained a strong
public health tradition that prioritizes the giving of
treatment over economic questions. A rights-based
approach to health care was formally reinforced by the
1997 Thai Constitution (section 52), which gives the
right to health and health care:
A person shall enjoy an equal right to receive stan-
dard public health services, and the indigent shall
have the right to receive free medical treatment
from public health centres of the State. . . . [20].
It is rare for health professionals or even professional
associations to consider the costs or value for money of
the services they offer to their patients because such
considerations, at least in public, would conﬂict with
their professional ethic to improve health and save life.
These historical and institutionalized ways of operat-
ing help to explain health professionals’ caution about
introducing economic evaluation. In principle, health
professionals must act in the patient’s best interest,
that is, where the basis of trust between the patient
and provider resides, and they will be reluctant to deny
an individual patient treatment on abstract rationales
based on “society’s interest” derived from economic
evaluation (unless, perhaps, rationales such as cost-
effectiveness can be explained clearly). The Constitu-
tion has added strength to health professionals’
caution, through fear of serious criticism or even
allegations of criminal negligence from the public if
they refuse treatment to patients. Other policy actors’
caution about economic evaluation was also inﬂu-
enced by these institutional contexts, particularly
health policy decision-makers at the national level
(politicians and bureaucrats) who are also medically
trained and are primarily responsible for ensuring
health-care services are available according to the
Constitution.
The political context and changing political pres-
sures on policymakers (number 5 in Fig. 1) were per-
ceived to be inevitable and legitimate forces inﬂuencing
decision-making, particularly for senior politicians and
bureaucrats. Economic evaluation information could
only be considered and weighed up in the light of these
political pressures, for example, the need to sustain
political legitimacy and popularity. Furthermore, the
introduction of economic evaluation would have
implications for the distribution of power within the
decision-making process. The interviews revealed poli-
cymakers’ concerns that if economic evaluation was to
be used as a signiﬁcant criterion for making coverage
decisions, their power and authority would be dimin-
ished and transferred to academics or economists.
Conclusions and Policy Recommendations
This study demonstrates that introducing economic
evaluation into health-care decision-making in settings
like Thailand is more complicated and likely to be
more difﬁcult than is commonly presumed to be in
the economic academic literature. In-depth interviews
with 36 policy actors located in different positions in
the health sector showed their lack of understanding
in the method. A basic policy measure to encourage the
use of economic evaluation among policymakers
would therefore be to offer awareness and education
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programs aimed at making policymakers more conﬁ-
dent in using and interpreting economic evaluation
evidence and more able to explain it to others.
In addition, many policy actors questioned the
ethical values underpinning QALY maximization.
QALY maximization may not be the only goal for
resource allocation and economic evaluation may not
be the only tool for decision-makers to ration health
care. Equity, necessity (severity of disease), social soli-
darity (helping the poor and vulnerable), and protec-
tion against catastrophic expenditure also play a
signiﬁcant role. These criteria are particularly impor-
tant in the context of the UC in Thailand because an
explicit objective of the UC policy was to increase
equity of coverage and reduce catastrophic spending.
Therefore, proposals to use economic evaluation
should not disregard or eliminate other criteria con-
cerning resource allocation, and a priority is to develop
an alternative approach for economic evaluation,
which incorporates criteria like equity and social soli-
darity to enhance political and public acceptance of a
health-care package.
This exploratory research has highlighted two areas
for further research. First, the opportunities and difﬁ-
culties of introducing economic evaluation into the
speciﬁc context of Thailand may be different in other
settings due to differences in health-care infrastructure,
institutions and incentives, and different policy pro-
cesses and political pressures. It would therefore be
valuable to learn to what extent the barriers to the use
of economic evaluation identiﬁed in Thailand are dis-
tinctive or similar to those operating in other low- and
middle-income countries.
Second, the ﬁndings revealed that public involve-
ment of some sort in coverage decisions was necessary
because decision-makers and health professionals were
sensitive to the public’s responses to their decisions.
Nevertheless, the study did not explore public or
patient perspectives on priority setting. Public perspec-
tives on health-care rationing cannot be ignored if
economic evaluation is to be accepted and trusted
as a legitimate means of resource allocation. More
research is therefore required to examine the public’s
acceptance of using economic evaluation or alter-
native resource allocation criteria for health-care
coverage decisions, and to examine possible mecha-
nisms for incorporating these public perspectives into
decision-making.
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